What’s the sensitivity required for optimal molecular testing in NSCLC? Dr. Erwan Pencreach presents the results from a retrospective technical analysis, after a year of routine NSCLC molecular testing with the MassARRAY System, from a biological/clinical and economical point of view.
Topics Include:
- Understand the role of driver mutations and actionable targets, like T790M, L858R and exon 19 deletions in EGFR.
- Supplement clinical analyses of routine NSCLC molecular testing with economic considerations.
- Evaluate the MassARRAY technology for melanoma, lung, breast and colon cancers in comparison with NGS.
Presented by:
Erwan Pencreach, PharmD, PhD
Department of Molecular Oncology, Strasbourg University Hospital, France
Recorded on July 28, 2020
Learn more about our liquid biopsy and tumor profiling solutions.